La cadena de opciones muestra datos clave de las opciones de acciones de Kezar Life Sciences a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Kezar Life Sciences..

Kezar Life Sciences (NASDAQ:KZR) Bolsa, Cadena de Opciones

Kezar Life Sciences

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.

Kezar Life Sciences Inc

Earnings

Earnings Beats

News

HBIO

Harvard Bioscience Q4 2024 Adj. EPS $0.06 Beats $0.05 Estimate, Sales $24.556M Beat $24.150M Estimate

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Eve Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVEX#NYSE">EVEX</a>) with a Buy and maintains $6 price target.

Price Target

Reiteration

Analyst Ratings

EVEX

HC Wainwright & Co. Reiterates Buy on Eve Holding, Maintains $6 Price Target

Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.05) by 60 percent. The company reported quarterly sales of $62.31 million which beat the analyst consensus estimate of $35.92 million by 73.48 percent. This is a 16.61 percent decrease over sales of $74.71 million the same period last year.

AMRN

Amarin Corp Q4 2024 Adj EPS $(0.02) Beats $(0.05) Estimate, Sales $62.31M Beat $35.92M Estimate

Chicago Atlantic Real (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFI#NASDAQ">REFI</a>) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.45 by 2.22 percent. This is a 13.21 percent decrease over earnings of $0.53 per share from the same period last year. The company reported quarterly sales of $14.07 million which missed the analyst consensus estimate of $15.81 million by 11.02 percent. This is a 5.20 percent decrease over sales of $14.84 million the same period last year.

Earnings Misses

REFI

Chicago Atlantic Real Q4 Adj $0.46 Beats $0.45 Estimate, Sales $14.07M Miss $15.81M Estimate

Biotech

General

RDHL

RedHill Biopharma Initiates Phase 2 Study Of RHB-204 In Mycobacterium Avium Subspecies Paratuberculosis-Positive Moderate To Severe CD

Smith Douglas Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDHC#NYSE">SDHC</a>) reported quarterly earnings of $0.46 per share which missed the analyst consensus estimate of $0.51 by 9.8 percent. The company reported quarterly sales of $287.49 million which beat the analyst consensus estimate of $265.88 million by 8.12 percent.

SDHC

Smith Douglas Homes Q4 2024 GAAP EPS $0.46 Misses $0.51 Estimate, Sales $287.49M Beat $265.88M Estimate

ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $0.78 by 11.54 percent. This is a 1.16 percent increase over earnings of $0.86 per share from the same period last year. The company reported quarterly sales of $2.11 billion which beat the analyst consensus estimate of $2.09 billion by 1.07 percent. This is a 2.17 percent increase over sales of $2.07 billion the same period last year.

ABM Indus Q1 2025 Adj EPS $0.87 Beats $0.78 Estimate, Sales $2.11B Beat $2.09B Estimate

iRobot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) reported quarterly losses of $(2.06) per share which missed the analyst consensus estimate of $(1.73) by 19.08 percent. This is a 13.19 percent decrease over losses of $(1.82) per share from the same period last year. The company reported quarterly sales of $172.03 million which beat the analyst consensus estimate of $171.00 million by 0.60 percent. This is a 44.06 percent decrease over sales of $307.54 million the same period last year.

IRBT

iRobot Q4 Adj $(2.06) Misses $(1.73) Estimate, Sales $172.03M Beat $171.00M Estimate

ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) reported quarterly earnings of $4.66 per share which beat the analyst consensus estimate of $3.49 by 33.52 percent. This is a 478.86 percent increase over losses of $(1.23) per share from the same period last year. The company reported quarterly sales of $2.17 billion which beat the analyst consensus estimate of $2.06 billion by 5.33 percent. This is a 79.92 percent increase over sales of $1.21 billion the same period last year.

ZIM Integrated Shipping Q4 2024 GAAP EPS $4.66 Beats $3.49 Estimate, Sales $2.17B Beat $2.06B Estimate

Cresco Labs (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) reported quarterly sales of $175.91 million which beat the analyst consensus estimate of $172.13 million by 2.19 percent. This is a 6.55 percent decrease over sales of $188.24 million the same period last year.

CRLBF

Cresco Labs Q4 Sales $175.91M Beat $172.13M Estimate, Net income of $0.4M

Geoblocking policies in cryptocurrency airdrops may have cost Americans up to $2.6 billion in potential earnings from 2020 to 2024, a report released Monday revealed.
What Happened:&nbsp;Dragonfly, a cryptocurrency-focused venture capital firm, published a <a href="https://airdropreport2025.dragonfly.xyz/Dragonfly-s-State-of-Airdrops-Report-2025-1b1af13b644180c8aff9c2bd0d222e14">report </a>detailing the financial impact of geoblocking policies on U.S. users in <a href="https://www.benzinga.com/money/what-is-a-crypto-airdrop">airdrops</a>—a marketing stunt that involves sending free tokens to users to promote a project and drive engagement.
According to the report, 11 out of the 12 airdrops analyzed used geoblockers to prevent&nbsp;U.S. residents from participating or&nbsp;receiving tokens. Due to these geographical restrictions, U.S. users may have missed out on anywhere&nbsp;between $1.84 and $2.64 billion&nbsp;in potential revenue from 2020-2024.
Moreover, the Treasury Department may have missed federal tax revenue of up to $1.38 billion due to geoblocked airdrop income. 
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/25/03/44267582/us-house-committee-favors-stablecoin-regulation-to-strenthen-dollar-advocates-against-cbdc">House Committee Favors Stablecoin Regulation To &#8216;Strengthen&#8217; Dollar: Majority Whip Says CBDCs Against &#8216;American Values&#8217;</a>
The report included analysis&nbsp;of token airdrops&nbsp;such as ApeCoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">APE</a>), linked to the Bored Ape Yacht Club non-fungible token, in addition to&nbsp;Arbitrum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">ARB</a>) and EigenLayer (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">EIGEN</a>).
Why It Matters: The SEC&#8217;s position on cryptocurrency airdrops has been ambiguous, with non-binding guidance in 2019 indicating that an airdrop &#8220;may constitute&#8221; a sale or distribution of securities. 
The agency hasn&#8217;t issued a comprehensive regulation, though, specifically addressing airdrops. To be on the safer side, many cryptocurrency projects started blocking U.S. residents from accessing airdrops.
A few <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40920107/gary-gensler-led-sec-should-clarify-crypto-airdrop-rules-gop-representatives-demand">prominent members</a> of Congress wrote to former SEC Chair Gary Gensler in September 2024, pressing for clarity on the regulatory stance. 
Over the years, scammers have <a href="https://www.benzinga.com/markets/cryptocurrency/24/01/36740248/hackers-steal-580-000-with-fake-airdrop-links-in-phishing-mail-scam">exploited the allure of airdrops</a> or free tokens to con unsuspecting users. The modus operandi involves creating fake airdrop campaigns, which impersonate legitimate projects, and then using deceptive tactics to trick users into connecting their wallets to phishing websites.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/03/44268317/sec-postpones-approval-of-several-crypto-spot-etfs-says-influential-analyst">Dogecoin, XRP ETF Filings Delayed By SEC But Influential Analyst Says &#8216;Relatively High&#8217; Odds Of Approval</a></li>
</ul>
Photo courtesy: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$APE

$ARB

$EIGEN

US Crypto Users Missed Receiving Over $2.5 Billion In Airdrops Due To Geoblocking: Report

Uranium Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UEC#AMEX">UEC</a>) reported quarterly sales of $49.80 million which beat the analyst consensus estimate of $41.40 million by 20.29 percent. This is a 42.83K percent increase over sales of $116.00 thousand the same period last year.

Uranium Energy Q2 Sales $49.80M Beat $41.40M Estimate

Uranium Energy Q2 Sales $49.800M Beat $41.400M Estimate

TD Securities analyst Andrew Charles reiterates First Watch Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) with a Hold and maintains $21 price target.

FWRG

TD Securities Reiterates Hold on First Watch Restaurant Gr, Maintains $21 Price Target

Magnachip Expects To Complete Strategic Process And Exit Display Business By The End Of Q2 This Year

MagnaChip Semiconductor Q4 2024 Adj. EPS $0.07 Beats $(0.19) Estimate, Sales $63.039M Beat $61.567M Estimate

Magnachip Explores All Strategic Options For Its Display Business, Which Will Be Classified As Discontinued Operations When It Reports Q1 Results In May

Benchmark analyst Cody Acree reiterates Silicon Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>) with a Buy and maintains $160 price target.

SLAB

Benchmark Reiterates Buy on Silicon Laboratories, Maintains $160 Price Target

Offerings

Gildan Activewear Prices Offering Of C$700M Of Senior Unsecured Notes In Three Series

Goldman Sachs forecasts a surge in U.S. copper imports soon, driven by expectations of tariffs from President Donald Trump's <a target="_blank" href="https://www.benzinga.com/topic/donald-trump" rel="noreferrer noopener">administration</a>.
Per Reuters' <a target="_blank" href="https://www.reuters.com/markets/commodities/goldman-sachs-anticipates-surge-us-copper-net-imports-2025-03-11/" rel="noreferrer noopener">report</a>, the investment bank expects a 25% duty on copper imports by year's end, incentivizing stockpiling to frontrun the legislative. As a result, U.S. net copper imports could surge by 50-100%, adding between 200,000 to 300,000 metric tons to domestic inventories by Q3.
If this projection materializes, U.S. copper stockpiles could swell from 95,000 tons to as much as 400,000 tons or around half of global reported inventories – leaving the international market at historically low inventory levels.
For 2025, Goldman sees a 180,000-ton global copper deficit as growing demand for electrification, economic stimulus measures in China, and slow mine growth materialize. The bank sees the supply imbalance more pronounced in the second half of the year as a catalyst for higher prices.
"We maintain our forecast that the LME three-month price will average $10,200 per ton in Q3 2024 and see the impact of inventory dislocation predominantly in timespreads," the bank noted. Current three-month copper contracts on the London Metal Exchange were trading at $9,528.50 per ton as of Wednesday morning.
The largest U.S. copper producer, Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>), could benefit from this scenario, particularly if copper is classified as a critical mineral.
In a recent <a target="_blank" href="https://www.reuters.com/markets/commodities/ceraweek-freeport-sees-500-million-annual-boost-if-trump-declares-copper-2025-03-10/" rel="noreferrer noopener">interview</a>, CEO Kathleen Quirk expressed optimism that the Trump administration could make this move soon, unlocking the federal tax incentives to support domestic production.
"Having the incentives and clarity around those would be a big plus for the domestic copper industry," Quirk said. Such a designation would enable Freeport to claim more than $500 million annually in tax credits tied to the Inflation Reduction Act.
Freeport-McMoRan operates seven copper mines across the U.S. and one of two domestic copper smelters. The firm doesn't export any domestically produced copper, making it a key supplier in any scenario restricting imports.
However, production costs in the U.S. are higher than in Freeport's international operations due to lower ore grades, making policy support a crucial factor.
Per the <a target="_blank" href="https://mms.businesswire.com/media/20250122679192/en/2360933/1/FCX_250123_4Q_2024_Earnings_Release.pdf" rel="noreferrer noopener">latest guidance</a>, the company expects its U.S. copper production to increase by 8% in 2025, with further growth in subsequent years. Opportunities include doubling the concentrator capacity at its Bagdad operation in Arizona, which could add 200-250 million pounds of copper annually.
Quirk also hinted at a possible <a target="_blank" href="https://www.benzinga.com/25/03/44216408/dr-congo-explores-a-minerals-for-security-deal-with-the-us" rel="noreferrer noopener">return to the Democratic Republic of Congo</a>, where Freeport previously owned the Kisanfu copper-cobalt project before selling it to China Molybdenum in 2020. "We would be interested in going back for the right opportunity," she said, adding that Freeport would seek to be the operator of any project if it re-enters the DRC.
Price Watch: Freeport-McMoRan has declined 5.28% year-to-date. The stock is up 1.56% to $36.44 premarket at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44243837/iron-ore-production-to-accelerate-until-2030-study-says" target="_blank" rel="noreferrer noopener">Iron Ore Production To Accelerate Until 2030, Study Says</a></li>
</ul>
Photo via Shutterstock

Government

Large Cap

Guidance

Commodities

Politics

Legal

Trading Ideas

COPX

CPER

FQVLF

JJCTF

LUNMF

MTAL

SCCO

Goldman Sachs Sees Copper Imports Frontrunning Tariffs As FCX Positions To Benefit

Press Releases

Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients

Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis

Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal

Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update

Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split

Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)

Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025

Comments

Kezar Life Sciences

Kezar Life Sciences (KZR) Opciones

Kezar Life Sciences (NASDAQ:KZR) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL